J Pharm Sci 104 (8): 2433–2440.
32 32 Ebbers, H.C., Crow, S.A., Vulto, A.G., and Schellekens, H. (2012). Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 30 (12): 1186–1190.
33 33 Esplugues, J.V., Flamion, B., and Puig, L. (2016). Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars. New Horiz Transl Med 3 (3–4): 161.
34 34 Moots, R., Azevedo, V., Coindreau, J.L. et al. (2017). Switching between reference biologics and biosimilars for the treatment of rheumatology, gastroenterology, and dermatology inflammatory conditions: considerations for the clinician. Curr Rheumatol Rep 19 (6): 37.
35 35 Biologics Prescribers Collaborative (BPC) (2018). Non‐Medical Switching Principles and Guidelines (16 March). www.biologicsprescribers.org/policy‐issues/non‐medical‐switching (accessed 20 June 2020).
36 36 French, T. (2018). Shared decision making in switching to biosimilars. Ann Rheum Dis 77 (Supplement 2): 7.
37 37 Cvancarova S.M., Brandvold, M., and Andenaes, R. (2018). Is patients' satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey. Ann Rheum Dis 77 (Supplement 2): 86.
38 38 McKinnon, R.A., Cook, M., Liauw, W. et al. (2018). Biosimilarity and interchangeability: principles and evidence. A systematic review. BioDrugs 32 (1): 27–52.
39 39 GaBi Online (2018). International policies for interchangeability, switching and substitution of biosimilars. http://gabionline.net/Reports/International‐policies‐for‐interchangeability‐switching‐and‐substitution‐of‐biosimilars (accessed 18 February 2020).
40 40 Milmo, S. (2016). Biosimilars: making the switch comes with challenges. More efforts are needed to raise awareness of biosimilars among physicians and patients in Europe and address scepticisms about the quality and safety of biosimilars. BioPharm Int 29 (6): 10–14.
41 41 Uhlig, T. and Goll, G.L. (2017). Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons. Rheumatology (Oxford) 56 (Suppl 4): iv49–iv62.
42 42 Gerrard, T.L., Johnston, G., and Gaugh, D.R. (2015). Biosimilars: extrapolation of clinical use to other indications. GaBI J 4 (3): 118–124.
43 43 McCamish, M. and Woollett, G. (2017). Molecular “sameness” is the key guiding principle for extrapolation to multiple indications. Clin Pharmacol Ther 101 (5): 603–605.
44 44 Pouillon, L., Socha, M., Demore, B. et al. (2018). The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol 14 (9): 739–749.
45 45 Povsic, M., Lavelle, P., Enstone, A., and Rousseau, B. (2018). Patient influence on biosimilar uptake: the nocebo effect. Value Health 21 (Supplement 3): S181.
46 46 Buttel, I.C., Chamberlain, P., Chowers, Y. et al. (2011). Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39 (2): 100–109.
47 47 Strand, V., Goncalves, J., Hickling, T.P. et al. (2018). Immunogenicity of biosimilars for rheumatic diseases: an updated review from regulatory documents and confirmatory clinical trials. Ann Rheum Dis 77 (Supplement 2): 1398.
48 48 World Health Organization, CIOMS (2018). Definitions. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/trainingcourses/definitions.pdf (accessed 20 February 2020).
49 49 European Medicines Agency (2014). Guideline on similar biological medicinal products containing biotechnology‐derived proteins as active substance: non‐clinical and clinical issues. https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐similar‐biological‐medicinal‐products‐containing‐biotechnology‐derived‐proteins‐active_en‐2.pdf (accessed 20 February 2020).
50 50 Calvo, B., Martinez‐Gorostiaga, J., and Echevarria, E. (2018). The surge in biosimilars: considerations for effective pharmacovigilance and EU regulation. Ther Adv Drug Saf 9 (10): 601–608.
51 51 Wechsler, J. (2018). Biosimilars raise manufacturing and regulatory challenges. Pharm Technol 42 (7): 14–15.
52 52 Gamez‐Belmonte, R., Hernandez‐Chirlaque, C., Arredondo‐Amador, M. et al. (2018). Biosimilars: concepts and controversies. Pharmacol Res 133: 251–264.
53 53 Ramanan, S. and Grampp, G. (2014). Drift, evolution, and divergence in biologics and biosimilars manufacturing. BioDrugs 28 (4): 363–372.
54 54 Declerck, P., Farouk‐Rezk, M., and Rudd, P.M. (2016). Biosimilarity versus manufacturing change: two distinct concepts. Pharm Res 33 (2): 261–268.
55 55 Rathore, A. (2009). Roadmap for implementation of quality by design (QbD) for biotechnology products. Trends Biotechnol 27 (9): 546–553.
56 56 Mitragotri, S., Burke, P., and Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 13 (9): 655–672.
57 57 Hooven, M.D. (2017). Opportunities and challenges in biologic drug delivery. American Pharmaceutical Review. https://www.americanpharmaceuticalreview.com/Featured‐Articles/345540‐Opportunities‐and‐Challenges‐in‐Biologic‐Drug‐Delivery (accessed 20 February 2020).
58 58 Kuhlmann, M. and Schmidt, A. (2014). Production and manufacturing of biosimilar insulins: implications for patients, physicians, and health care systems. Biosimilars 4: 45–58. https://doi.org/10.2147/BS.S36043.
59 59 Jordan, B. (2019). U.S. biologics and biosimilars need distinguishable names. Stat News. https://www.statnews.com/2019/04/23/biologics‐biosimilars‐distinguishable‐names (accessed 20 February 2020).
60 60 DiGrande, S. (2018). Australian Government announces decision on biosimilar naming conventions. The Center for Biosimilars. https://www.centerforbiosimilars.com/news/australian‐government‐announces‐decision‐on‐biosimilar‐naming‐conventions (accessed 20 February 2020).
61 61 U.S. Food and Drug Administration (2020). Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. https://www.fda.gov/drugs/therapeutic‐biologics‐applications‐bla/purple‐book‐lists‐licensed‐biological‐products‐reference‐product‐exclusivity‐and‐biosimilarity‐or (accessed 18 June 2020).
62 62 EGA (2010). Biosimilars handbook. https://www.medicinesforeurope.com/wp‐content/uploads/2016/03/EGA_BIOSIMILARS_handbook_en.pdf (accessed 20 February 2020).
63 63 GaBi (2020). About GaBi journal. http://gabi‐journal.net/gabi‐journal/about‐gabi‐journal (accessed 18 June 2020).
64 64 FDA (2016). Implementation of the Biologics Price Competition and Innovation Act of 2009.